Advertisement

Trinity Biotech plc TRIB

Set alert

Price alert · TRIB

All alert types
6.26 USD -0.37 -5.58%

At close · Oct 30

6.71 +0.45 +7.24%

After hours · Oct 30, 4:00 PM ET

Bid
6.26 × 1
Ask
6.53 × 2
6.26 Day range 6.43
5.69 52-week range 38.40
YTD
-73.59%
1 year
-79.13%
Open
6.43
Prev close
6.63
Mkt cap
5.09M
Vol
6.70K
Avg vol
19.14K
EPS
-60.00
P/E
0.00
Div yield
0.00%
More statistics
Low
6.26
High
6.43
Forward P/E
-0.87
Beta
1.13
Short ratio
0.43
Inst. own
23.96%
Dividend
0.00
Ex-div date
Jun 4, 2015
50-d avg
1.39
200-d avg
1.90
1y target
0.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 15, 2024Earnings: -0.43; estimate -0.54; surprise 20.37%
  • Jul 24, 2026Split: 1 for 30
Signals (87)
NameDateAgo
MACD: Sell SignalOct 30, 20262 days ago
MACD: Buy SignalOct 6, 20263 weeks ago
MACD: Sell SignalOct 2, 20261 month ago
MACD: Buy SignalSep 28, 20261 month ago
RSI: OversoldSep 23, 20261 month ago
RSI: OversoldSep 10, 20261 month ago
MACD: Sell SignalAug 21, 20262 months ago
RSI: OversoldJul 24, 20263 months ago
MACD: Buy SignalJul 10, 20263 months ago
RSI: OversoldJun 23, 20264 months ago
SMA: BearishJun 16, 20264 months ago
MACD: Sell SignalJun 12, 20264 months ago
SMA: BullishMay 26, 20265 months ago
MACD: Buy SignalMay 21, 20265 months ago
MACD: Sell SignalApr 27, 20266 months ago
SMA: BearishApr 23, 20266 months ago
SMA: BullishApr 16, 20266 months ago
SMA: BearishApr 15, 20266 months ago
SMA: BullishApr 14, 20266 months ago
SMA: BearishApr 13, 20266 months ago
SMA: BullishApr 10, 20266 months ago
MACD: Buy SignalApr 7, 20266 months ago
MACD: Sell SignalMar 20, 20267 months ago
SMA: BearishMar 17, 20267 months ago
SMA: BullishMar 13, 20267 months ago
MACD: Buy SignalMar 11, 20267 months ago
MACD: Sell SignalMar 10, 20267 months ago
MACD: Buy SignalMar 6, 20268 months ago
MACD: Sell SignalFeb 17, 20268 months ago
MACD: Buy SignalFeb 6, 20268 months ago
MACD: Sell SignalFeb 5, 20268 months ago
SMA: BearishJan 29, 20269 months ago
SMA: BearishJan 29, 20269 months ago
SMA: BullishJan 23, 20269 months ago
SMA: BullishJan 23, 20269 months ago
MACD: Buy SignalJan 22, 20269 months ago
SMA: BearishDec 29, 202510 months ago
SMA: BearishDec 29, 202510 months ago
MACD: Sell SignalDec 29, 202510 months ago
SMA: BullishDec 23, 202510 months ago
MACD: Buy SignalDec 23, 202510 months ago
MACD: Sell SignalDec 16, 202510 months ago
SMA: BearishDec 15, 202510 months ago
RSI: OverboughtDec 9, 202510 months ago
SMA: BullishDec 8, 202510 months ago
SMA: BearishDec 5, 202511 months ago
SMA: BullishNov 28, 202511 months ago
MACD: Buy SignalNov 25, 202511 months ago
SMA: BullishNov 24, 202511 months ago
SMA: BearishNov 17, 202511 months ago
SMA: BullishNov 14, 202511 months ago
SMA: BearishNov 13, 202511 months ago
MACD: Sell SignalNov 11, 202511 months ago
MACD: Buy SignalOct 28, 20251 year ago
MACD: Sell SignalOct 16, 20251 year ago
MACD: Buy SignalOct 14, 20251 year ago
SMA: BearishSep 26, 20251 year ago
MACD: Sell SignalAug 29, 20251 year ago
RSI: OverboughtAug 14, 20251 year ago
RSI: OverboughtAug 12, 20251 year ago
RSI: OverboughtAug 5, 20251 year ago
MACD: Buy SignalAug 4, 20251 year ago
SMA: BullishJul 31, 20251 year ago
SMA: BearishJul 24, 20251 year ago
MACD: Sell SignalJul 21, 20251 year ago
SMA: BullishJul 3, 20251 year ago
SMA: BearishJul 2, 20251 year ago
SMA: BullishJul 1, 20251 year ago
SMA: BearishJun 26, 20251 year ago
MACD: Buy SignalJun 25, 20251 year ago
SMA: BullishJun 24, 20251 year ago
SMA: BearishJun 12, 20251 year ago
SMA: BullishJun 11, 20251 year ago
SMA: BearishMay 27, 20251 year ago
MACD: Sell SignalMay 21, 20251 year ago
RSI: OverboughtMay 2, 20251 year ago
SMA: BullishApr 25, 20251 year ago
MACD: Buy SignalApr 11, 20251 year ago
MACD: Sell SignalMar 31, 20251 year ago
MACD: Buy SignalMar 11, 20251 year ago
MACD: Sell SignalMar 3, 20251 year ago
MACD: Buy SignalFeb 24, 20251 year ago
MACD: Sell SignalFeb 7, 20251 year ago
SMA: BearishJan 30, 20251 year ago
SMA: BullishJan 28, 20251 year ago
RSI: OverboughtJan 28, 20251 year ago
RSI: OversoldDec 26, 20241 year ago

Key statistics

Market cap
24.68M
Enterprise value
347.37M
Trailing P/E
0.00
Forward P/E
-0.87
PEG ratio
0.00
Price / sales
0.42
Price / book
0.00
EPS (TTM)
-2.25
Beta
1.13
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-38.01%
Revenue (TTM)
58.65M
Revenue growth
14.00%
Free cash flow
-9.93M
Total cash
5.32M
Total debt
93.33M
Return on equity
0.00%
Shares outstanding
27.52M
Short % of float
2.43%
50-day average
1.39
200-day average
1.90

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate -0.30.

Earnings history

Financials — quick view

All financials
TRIB Revenue — quarterly 15.86M
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
TRIB Net income — quarterly -16.96M
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024

Earnings

TRIB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 15, 2024Sep 1, 2024-0.54-0.43+0.11+20.37%
Aug 14, 2024Jun 1, 2024-0.65-0.55+0.10+15.38%
May 23, 2024Mar 1, 20240.00-0.37——
Apr 4, 2024Dec 1, 20230.00-0.68——
Oct 3, 2023Jun 1, 20230.00-1.00——
Jul 6, 2023Mar 1, 20230.00-0.80——

About Trinity Biotech plc

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Sector
Healthcare
Industry
Medical Devices
Country
Ireland

News

Your note

Sign in to keep a note on TRIB — it syncs with the Stock Master app.

Institution ownership

TRIB institution ownership
Holder% heldSharesValueReported
Perceptive Advisors Llc79.72%1,800,0001.61MSep 29, 2024
Hunter Associates Investment Management LLC15.93%359,810322.75KSep 29, 2024
Renaissance Technologies, LLC11.08%250,153224.39KSep 29, 2024
Whitefort Capital Management, LP3.63%81,90273.47KSep 29, 2024
Acadian Asset Management. LLC1.85%41,83937.53KSep 29, 2024
HRT Financial LP1.51%34,03030.52KSep 29, 2024

Fund ownership

TRIB fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.22%5,0774.55KOct 30, 2024
Advertisement